Business Context and Reporting Period
Silexion Therapeutics Corp (SLXN), a Cayman Islands-based emerging growth company, filed a Form 8-K on September 26, 2025. The filing reports the entry into a material definitive agreement to establish an "At The Market" (ATM) equity offering program.
Key Financial Metrics
This filing does not contain audited financial statements, revenue, profit, cash flow, or margin data. The primary financial metric disclosed is the authorization to raise up to $13.17 million through the sale of ordinary shares. The company will pay a 3% cash commission to the agent, H.C. Wainwright & Co., LLC, on gross sales proceeds.
Material Changes
The material change reported is the execution of the Offering Agreement on September 26, 2025. This agreement allows the company to sell ordinary shares from time to time through Wainwright via ordinary brokers' transactions on The Nasdaq Capital Market. The company is not obligated to sell any shares under this agreement.
Guidance, Outlook, and Risks
The filing does not provide specific financial guidance or management commentary on future operational performance. The offering is contingent upon the effectiveness of a shelf registration statement on Form S-3 filed on the same date. The agreement may be terminated by either the Company or Wainwright at any time. The filing includes standard legal disclaimers that the report does not constitute an offer to sell securities in jurisdictions where such an offer would be unlawful.
Investor Verification Checklist
- Verify the effectiveness status of the Form S-3 shelf registration statement filed on September 26, 2025.
- Review the full text of the At The Market Offering Agreement (Exhibit 10.1) for specific termination rights and conditions.
- Monitor subsequent filings for actual share sales and proceeds generated under the $13.17 million program.
- Check the company's most recent 10-K or 10-Q for current cash position and liquidity needs driving this offering.